Application of ADGRE5 gene in preparation of antitumor drugs and screening method of ADGRE5 gene

By knocking down the ADGRE5 gene of tumor cells and screening immune checkpoint molecules using small interfering RNA library, the problem of tumor cells evading NK cell recognition and killing was solved, significantly enhanced the anti-tumor activity of NK cells, inhibited tumor growth, and provided new therapeutic targets and directions.

CN120000795APending Publication Date: 2025-05-16JILIN UNIVERSITY
0 Cites 0 Cited by

Patent Information

Application Number
CN202510208796.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-02-25
Publication Date
2025-05-16

AI Technical Summary

Technical Problem

Tumor cells block the recognition and killing functions of NK cells through various pathways, resulting in immune escape. The existing technology is difficult to effectively solve this problem.

Method used

By knocking down the ADGRE5 gene of tumor cells, the anti-tumor activity of NK cells was enhanced, and a small interfering RNA library combined with IFN-γ and LDH detection was used to screen out potential immune checkpoint molecules that inhibit the anti-tumor activity of NK cells.

Benefits of technology

It significantly improves the killing activity of NK cells on tumor cells, inhibits tumor growth, promotes the infiltration and activity of NK cells and T cells in the tumor, provides new targets and directions, and brings more accurate and effective treatment plans to patients.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention is applicable to the technical field of biological medicines, and provides application of an ADGRE5 gene in preparation of antitumor drugs and a screening method of the ADGRE5 gene. According to the invention, the ADGRE5 gene, which is a key inhibition molecule related to the antitumor activity of NK cells, is successfully recognized. The discovery not only provides a new insight for an immune defense mechanism of malignant tumors, but also opens up a new target and direction for the field of immunotherapy, and is expected to bring a more accurate and effective therapeutic scheme for patients. The screening method provided by the invention has the advantages of short period, convenience in operation, high reliability and the like; according to the method, the primary NK cells of healthy donors are adopted, and strict in-vivo and in-vitro verification is carried out, so that the accuracy and reliability of data are ensured. The method not only provides a new means for identifying and targeting an immune escape mechanism of malignant tumor cells, but also provides a practical tool and a potential therapeutic target for developing a tumor immune defense strategy based on the NK cells, and has a wide clinical application prospect.
Need to check novelty before this filing date? Find Prior Art